Hansa Biopharma (HNSA) announced that Hitto Kaufmann has been appointed as Hansa’s chief scientific officer, or CSO, effective December 1. As CSO, Kaufmann will be responsible for all research, early development, translational and manufacturing activities. He will report to president and CEO Soren Tulstrup and serve as a member of Hansa’s executive committee. Kaufmann joins Hansa from Pieris Pharmaceuticals (PIRS) where he has served as chief scientific officer since 2019.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PIRS:
- Biotech Alert: Searches spiking for these stocks today
- Pieris Pharmaceuticals achieves milestone payment from Boston Pharmaceuticals
- Pieris Pharmaceuticals trading resumes
- Pieris Pharmaceuticals announces restructuring, to reduce workforce by 70%
- Pieris Pharmaceuticals trading halted, news pending
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue